Although the cure rate of childhood ALL is among the highest of any cancers, there is still significant room for improvement both because some children still succumb to their disease and because others may obtain more treatment than is necessary for cure. Almost all children enter remission following initial therapy, but may patients harbor residual disease below the level that can be detected by conventional measurements. There is a growing body of evidence that presence of this minimal residual disease (MRD) may be an adverse prognostic factor. This project is designed to study children with ALL who are enrolled on front-line clinical trials of the Pediatric Oncology Group for newly diagnosed leukemia. The current study will employ a highly sensitive four color flow cytometric technique to study MRD and will answer the following questions: 1) What is the frequency with which children with ALL have phenotypically abnormal cells in the bone marrow or blood following induction therapy, or at the end of consolidation therapy, and what is the quantitative residual disease burden in such patients? 2) How dose the presence of MRD correlate with traditional risk factors? 3) Do patients with MRD have an increased risk of relapse and what quantitative level of positivity is optimal for distinguishing between higher and lower risk patients? 4) Do children with ALL who harbor MRD and receive more intensive therapy have a better outcome than those who do not receive this extra therapy? In preliminary experiments, he has found that he can detect residual leukemic blasts in the blood or marrow of some patients at the end of induction therapy. The range of postivity he has detected so far is from 0.33 percent to as low as .0054 percent of total cells. The studies described here will be closely integrated with other studies proposed in a companion grant as part of this IRPG. These other proposed studies will use molecular techniques to detect residual disease on the same samples tested here. Another goal of their study therefore is to compare flow and molecular technologies and determine the most sensitive, most predictive, and most cost-effective technical approach for the detection of clinically significant residual leukemic burden.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA086011-01
Application #
6094592
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Wu, Roy S
Project Start
2000-04-01
Project End
2005-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
1
Fiscal Year
2000
Total Cost
$439,009
Indirect Cost
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Borowitz, Michael J (2014) Mixed phenotype acute leukemia. Cytometry B Clin Cytom 86:152-3
Dunsmore, Kimberly P; Devidas, Meenakshi; Linda, Stephen B et al. (2012) Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 30:2753-9
Chen, I-Ming; Harvey, Richard C; Mullighan, Charles G et al. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119:3512-22
Bowman, W Paul; Larsen, Eric L; Devidas, Meenakshi et al. (2011) Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer 57:569-77
Maloney, Kelly W; Carroll, William L; Carroll, Andrew J et al. (2010) Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 116:1045-50
Yang, Jun J; Cheng, Cheng; Yang, Wenjian et al. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403
Mullighan, Charles G; Su, Xiaoping; Zhang, Jinghui et al. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-80
Borowitz, Michael J; Devidas, Meenakshi; Hunger, Stephen P et al. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111:5477-85
Borowitz, Michael J; Pullen, D Jeanette; Winick, Naomi et al. (2005) Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 68:18-24
Borowitz, M J; Pullen, D J; Shuster, J J et al. (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 17:1566-72